Two potential therapies for preventing myofibroblast differentiation

December 6, 2013 by April Reese Sorrow
New targets identified to combat tissue fibrosis
Somanath Shenoy is an associate professor of Clinical and Experimental Therapeutics in the UGA College of Pharmacy.

Multiple types of cells are needed for patients to recover from surgery or to restore life to tissues that have lost circulation. University of Georgia researchers have identified how the cells involved in the final stage of repair, myofibroblasts, are switched on. This information can lead to drug development that could speed recovery.

Injuries heal when inflammatory cells remove dead tissues, and new blood vessels form to supply nutrients for new tissue to grow. Another necessary step in the healing process is the addition of fibroblasts, cells that build the structural framework to connect tissues. If this final stage of repair, called the fibroblast-mediated repair, becomes uncontrolled it can lead to .

"Fibrotic scars formed in the brain after a stroke and myocardial infarction in the heart are major roadblocks for recovery," said Somanath Shenoy, associate professor with the UGA College of Pharmacy.

Other examples of fibrosis include alcohol- and hepatitis-induced liver fibrosis, stiffening of blood vessels during and a dangerous clinical condition called , which has no approved treatment except for a lung transplant.

Shenoy and his colleagues at the UGA Center for Pharmacy and Experimental Therapeutics led a recent study looking into pathological significance of Akt activity in the generation of , which is an underlying cause of fibrotic diseases. Akt is a specific protein kinase responsible for sugar metabolism, cell migration and transcription.

"In our study, we focused on the molecular mechanisms regulating the 'switch' from physiological fibroblasts to pathological myofibroblasts, and we identified a new signaling pathway in fibroblasts that regulates this pathologic switch, which is an Akt kinase-mediated pathway involving transcription factors Serum response factor and myocardin," Shenoy said. "We used biochemical, genetic, transgenic mouse and a translational approach to test our hypothesis and characterize the role of Akt-SRF-myocardin signaling axis in myofibroblast differentiation."

The results of the study are available at .

The study tested two potential therapies for preventing myofibroblast differentiation: an Akt inhibitor and an SRF inhibitor.

Previous work by Shenoy has shown transient activation of the Akt pathway by fibroblast growth factor is necessary for tissue recovery following a wound and ischemia tissue injury. The current study identified for the first time that sustained and uncontrolled Akt activation is integral for myofibroblast differentiation and tissue fibrosis.

The study also tested three compounds-triciribine (Akt inhibitor), rapamycin (mTOR inhibitor) and CCG1423 (SRF inhibitor)-for their therapeutic benefits in preventing myofibroblast differentiation. The medications were tested for their ability to reverse the switch from pathological myofibroblasts to more normal fibroblasts.

"The inhibition of Akt by triciribine will blunt the transforming growth factor beta-induced myofibroblast differentiation," said Maha Abdalla, lead author of the paper and doctoral candidate in Shenoy's laboratory. "The effect of hypoxia on myofibroblast formation and pulmonary artery remodeling was blunted in mice lacking the Akt gene."

"Altogether, we identified the novel mechanisms regulating tissue fibrosis and demonstrated the potential therapeutic benefits of triciribine (an Akt inhibitor) for fibrotic disorders such as hepatic and idiopathic pulmonary fibrosis," Abdalla said.

The study was funded by UGA College of Pharmacy dean's special endowment funds, American Heart Association grant #0830326N and National Institutes of Health grant #R01HL103952.

The research team is currently investigating the therapeutic potential of Akt inhibitors for the treatment of pulmonary hypertension using a mouse model.

Explore further: Pulmonary fibrosis: Between a ROCK and a hard place

Related Stories

Pulmonary fibrosis: Between a ROCK and a hard place

February 22, 2013
Pulmonary fibrosis is a scarring or thickening of the lungs that causes shortness of breath, a dry cough, fatigue, chest discomfort, weight loss, a decrease in the ability of the lungs to transmit oxygen to the blood stream, ...

Scientists offers way to disrupt fibrosis

November 10, 2013
A team of scientists that includes Saint Louis University researchers has identified a new way to intervene in the molecular and cellular cascade that causes fibrosis – a condition where the body's natural process of forming ...

Researchers pinpoint sources of fibrosis-promoting cells that ravage organs

July 1, 2013
Scientists have tracked down and quantified the diverse origins of cells that drive fibrosis, the incurable, runaway wound-healing that scars and ultimately destroys organs such as the lungs, liver and kidneys.

Study adds to efforts to find more effective anti-inflammatory drugs

September 27, 2012
Researchers have discovered a previously unknown function for a protein that could add to the expanding arsenal of potential new drugs for battling inflammation and tissue fibrosis in a number of disease processes.

Protein kinase Akt identified as arbiter of cancer stem cell fate, paper reports

December 20, 2012
(Medical Xpress)—The protein kinase Akt is a key regulator of cell growth, proliferation, metabolism, survival, and death. New work on Akt's role in cancer stem cell biology from the lab of senior author Honglin Zhou, MD, ...

Researchers find more clues to causes of breast cancer

October 27, 2011
Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component ...

Recommended for you

Novel approach to track HIV infection

August 18, 2017
Northwestern Medicine scientists have developed a novel method of tracking HIV infection, allowing the behavior of individual virions—infectious particles—to be connected to infectivity.

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

Can previous exposure to west Nile alter the course of Zika?

August 15, 2017
West Nile virus is no stranger to the U.S.-Mexico border; thousands of people in the region have contracted the mosquito-borne virus in the past. But could this previous exposure affect how intensely Zika sickens someone ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.